Trial · NCT07405671
Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
NCT07405671, Phase 4, Recruiting, Universitaire Ziekenhuizen KU Leuven
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation. Trials, record NCT07405671. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07405671
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
- NCT number
- NCT07405671
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 988 participants, estimated
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Conditions
- Atrial Fibrillation (AF), Coronary Artery Disease
- Interventions
- flecainide, Sotalol or Amiodarone
- First posted
- 2026-02-12
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite safety outcome | 1 year | The primary outcome measure is a composite safety outcome including all-cause mortality, severe adverse events leading to drug discontinuation, and unscheduled hospitalisation for heart failure or acute coronary syndrome. Each of these individual components is assessed as secondary outcome. |
| Secondary | All-cause mortality | 1 year | Death from any cause |
| Secondary | Severe adverse events leading to drug discontinuation | 1 year | Any severe AE leading to intervention discontinuation, including bradyarrhythmias, ventricular arrhythmias, atrial flutter with 1:1 conduction, QT/QRS prolongation, serious extra-cardiac adverse events |
| Secondary | Unscheduled hospitalisation for heart failure or acute coronary syndrome | 1 year | Unscheduled hospitalisation for heart failure or acute coronary syndrome |
| Secondary | AF recurrence | 1 year | Freedom from fast atrial arrhythmia post-treatment (clinical recurrence of AF) |
| Secondary | Major adverse cardiovascular events | 1 year | Composite of cardiovascular death, myocardial infarction, stroke |
| Secondary | Catheter ablation | 1 year | Incidence of catheter ablation for AF during follow-up |
| Secondary | Cardiovascular hospitalisation duration | 1 year | Total number of days of cardiovascular hospitalisation |
| Secondary | Treatment-related adverse events | 1 year | All serious adverse events and adverse events: * Frequency and severity of all treatment-emergent adverse events * Proportion of participants experiencing at least one AE/SAE. * Specific drug-related adverse events (e.g., QT prolongation, proarrhythmia, bradycardia, hypotension, fatigue, gastrointestinal disturbances). |
| Secondary | Cardiac function - LVEF | 3 months | Changes in cardiac function assessed by left ventricular ejection fraction expressed in percentages (%) from baseline measured by echocardiography |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07405671
GET https://conductscience.org/api/trials/v1/NCT07405671/registered